Back to Archived News
ChromoCure to Secure Patents on Proprietary Chromosomal Cancer Detection Technology as Foundation in Preparation for Cancer Therapy and Cure Research
Wednesday, January 27, 2010
Reno, NV -- ChoromCure, Inc. announced today, based on the recent validation of its cancer detection approach and efficacy of its proprietary Chromosomal Scanning Technology, that it has retained Patent & Intellectual Property Attorneys to assess its growing Intellectual Property portfolio and secure necessary filings and Patent protections. A complex and innovative series of systems, processes, cell preparation techniques and diagnostic algorithms are currently integrated in ChromoCure's landmark Chromosomal Scanning Technology.
The Company recently announced it will accelerate the implementation of its Cancer Therapy and Cure initiatives. The Intellectual Property audit and subsequent Patent Applications and protections will provide the required foundation for various research programs and collaborations.
ChromoCure's chromosomal approach to cancer detection, therapy and cure has been validated by recent publications, including the Mayo Clinic findings. Per the publication of the company's clinical collaboration and testing, its proprietary Chromosomal Scanner technology was demonstrated a reliable and effective automated technological system to detect aneuploid cells in real-world specimens, that detection of aneuploid cells is diagnostic of cervical lesions and that the Chromosomal Scanner possesses superb performance at not only detecting cancer but achieving the near theoretical maximum agreement with the collaborating clinic's error containing data.
The Company's pioneering knowledge of cancer's chromosomal properties invites very effective, non-toxic therapeutic strategies. ChromoCure's understanding of cancer's chromosomal peculiarities provides the most promising avenue for treatment and cure and reinforces its pioneering status.
ChromoCure develops and provides proprietary cancer detection systems and technologies. The Company's proprietary ChromoCure CS200 Chromosomal Scanner system has been proven accurate and efficient in the measurement of the unique genomic characteristic found in 100% of all cancers and never found in normal cells. The Company's technology has been proven to have an effective accuracy of 100% for all cancers at all stages and believes its technology will become the worldwide gold standard for cancer detection, progression measurement, and research for both therapy and cure.
This release contains statements or projections regarding future performance that is forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those projected as a result of certain risks and uncertainties. The company's filings contain various RISK FACTORS (and are incorporated herein by reference) and should be read before any investment decision.
Back to Archived News